iShares U.S. Pharmaceuticals ETF Fundamental Analysis (AMEX: IHE)
iShares U.S. Pharmaceuticals ETF Fundamental Analysis (AMEX: IHE)
iShares U.S. Pharmaceuticals ETF (AMEX: IHE) shows weak financial fundamentals with a PE ratio of 29.91, profit margin of 0.00%, and ROE of 0.00%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 25.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze IHE's fundamental strength across five key dimensions:
Efficiency Score
WeakIHE struggles to generate sufficient returns from assets.
Valuation Score
WeakIHE trades at a premium to fair value.
Growth Score
ModerateIHE shows steady but slowing expansion.
Financial Health Score
ModerateIHE shows balanced financial health with some risks.
Profitability Score
WeakIHE struggles to sustain strong margins.
Key Financial Metrics
Is IHE Expensive or Cheap?
P/E Ratio
IHE trades at 29.91 times earnings. This indicates a fair valuation.
Debt/Equity
iShares U.S. Pharmaceuticals ETF has a debt-to-equity ratio of 0.00, indicating its leverage.
Dividend Yield
The dividend yield of 1.37% provides an income stream to investors.
How Well Does IHE Make Money?
Net Profit Margin
For every $100 in sales, iShares U.S. Pharmaceuticals ETF keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.00 in profit for every $100 of shareholder equity.
ROA
iShares U.S. Pharmaceuticals ETF generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $0.00 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
N/A
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
N/A
vs 25 benchmark
P/B Ratio
Price to book value ratio
N/A
vs 25 benchmark
P/S Ratio
Price to sales ratio
N/A
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.00
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How IHE Stacks Against Its Sector Peers
| Metric | IHE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | N/A | 21.10 | N/A |
| ROE | 0.00% | 652.00% | Weak |
| Net Margin | 0.00% | -1585.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.91 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 910.69 | Weak Liquidity |
| ROA | 0.00% | -574.00% (disorted) | Weak |
IHE outperforms its industry in 1 out of 5 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews iShares U.S. Pharmaceuticals ETF's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical